Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 randomized study of INV-202 in diabetic kidney disease
2022-002140-51Phase 2Completed
- Sponsor
- Inversago
- Start
- Sep 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of monlunabant in diabetic glomerulosclerosis (3 arms), sponsored by Inversago. Primary endpoint: Change in UACR from baseline to Week 16. Started Sep 2022; status: completed.
02
Drugs
monlunabant
03
Conditions
diabetic glomerulosclerosis
Beyond the preview
Go deeper on 2022-002140-51.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-002140-51.